The Washington Post discussed the cost of the Obama's administration's plans to close the "doughnut hole" gap in the Medicare drug benefit. The piece never mentions the fact that the United States pays far more for prescription drugs than any other country because it gives drug companies unlimited patent monopolies, allowing them to charge whatever price they want during the period in which they are granted a legal monopoly. By contrast, every other wealthy country restricts the ability of drug companies to exploit this monopoly by negotiating lower prices. If the people in the United States paid the same prices for drugs as people In Canada or Germany, then the doughnut hole could be eliminated and the drug benefit would cost less than it does currently.
The article asserts at one point that 75 percent of seniors have enrolled in the Medicare drug program. This is misleading since the number includes people in Medicaid, in retiree health plans and in Medigap plans that receive subsidies from the drug benefit program.
There's too much at stake this November for us to quit. As we navigate another presidential election year, thoughtful independent journalism is more important than ever. We're committed to bringing you the latest news on what's really happening across the country this election season, shining a light on the stories corporate media overlooks and keeping the public informed about how power really works in America.
Quality reporting doesn't come for free, and we don't have corporate backers to rely on to fund our work. Everything we do is thanks to our incredible community of readers, who chip in a few dollars at a time to make what we do possible. This month, we're trying to raise $50,000 to help fuel our election coverage, and we've fallen behind on reaching our goal. Any amount you give today will bring us closer to making our reporting possible—and a generous donor has agreed to match all online donations, so your impact will be doubled.
